ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis

Juan Feng,Shan-Shan Lu,Ta Xiao,Wei Huang,Hong Yi,Wei Zhu,Songqing Fan,Xue-Ping Feng,Jiao-Yang Li,Zheng-Zheng Yu,Song Gao,Guo-Hui Nie,Yao-Yun Tang,Zhi-Qiang Xiao

DOI: https://doi.org/10.1158/0008-5472.can-20-0560

IF: 11.2

2020-10-16

Cancer Research

Abstract:Overexpression of ANXA1 and EphA2 has been linked to various cancers and both proteins have attracted considerable attention for the development of new anticancer drugs. Here we report that ANXA1 competes with Cbl for binding EphA2 and increases its stability by inhibiting Cbl-mediated EphA2 ubiquitination and degradation in nasopharyngeal carcinoma (NPC). Binding of ANXA1 to EphA2 promoted NPC cell growth and metastasis in vitro and in vivo by elevating EphA2 levels and increasing activity of EphA2 oncogenic signaling (pS897-EphA2). Expression of ANXA1 and EphA2 was positively correlated and both were significantly higher in NPC tissues than in the normal nasopharyngeal epithelial tissues. Patients with high expression of both proteins presented poorer disease-free survival and overall survival relative to patients with high expression of one protein alone. Furthermore, amino acid residues 20-30aa and 28-30aa of the ANXA1 N-terminus bound EphA2. An 11 amino acid–long ANXA1-derived peptide (EYVQTVKSSKG) was developed on the basis of this N-terminal region, which disrupted the connection of ANXA1 with EphA2, successfully downregulating EphA2 expression and dramatically suppressing NPC cell oncogenicity in vitro and in mice. These findings suggest that ANXA1 promotes NPC growth and metastasis via binding and stabilization of EphA2 and present a strategy for targeting EphA2 degradation and treating NPC with a peptide. This therapeutic strategy may also be extended to other cancers with high expression of both proteins.Significance:These findings show that EphA2 is a potential target for NPC therapeutics and an ANXA1-derived peptide suppresses NPC growth and metastasis.Graphical http://cancerres.aacrjournals.org/content/canres/80/20/4386/F1.large.jpg.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: to explore the role of the interaction between ANXA1 (Annexin A1) and EphA2 (Eph receptor A2) in the growth and metastasis of nasopharyngeal carcinoma (NPC), and to develop a polypeptide based on ANXA1 to inhibit this interaction, thereby providing a new strategy for the treatment of NPC.

Specifically, the study found that ANXA1 promotes the proliferation and metastasis of nasopharyngeal carcinoma cells by binding to EphA2 and stabilizing its expression. ANXA1 competes with Cbl for binding to EphA2, inhibiting Cbl - mediated ubiquitination and degradation of EphA2, thereby increasing the stability of EphA2. In addition, the N - terminal region of ANXA1 (especially the 20 - 30 amino acid residues) is crucial for binding to EphA2. Based on this finding, the researchers developed an eleven - amino - acid polypeptide (EYVQTVKSSKG) derived from the N - terminal of ANXA1. This polypeptide can disrupt the binding between ANXA1 and EphA2, leading to down - regulation of EphA2 expression and significantly inhibiting the carcinogenicity of nasopharyngeal carcinoma cells.

Therefore, this study aims to reveal the specific mechanism of the ANXA1 - EphA2 interaction in nasopharyngeal carcinoma and propose a new treatment strategy, that is, to inhibit the growth and metastasis of nasopharyngeal carcinoma by targeting EphA2 degradation. This not only provides new ideas for the treatment of nasopharyngeal carcinoma, but also has potential application prospects for the treatment of other cancers with high expression of ANXA1 and EphA2.